AstraZeneca has upgraded its revenue and earnings outlook for the year as it reported better-than-expected third-quarter results despite intensifying generic competition for blockbuster heartburn pill Nexium.
from WSJ.com: US Business http://ift.tt/1kv8P3h
via IFTTT
No comments:
Post a Comment